Atul Deodhar

Oregon Health & Science University — United States

Medicine · Health Sciences

62h-index16.4kcitations462works3.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Spondyloarthritis Studies and Treatments(334), Rheumatoid Arthritis Research and Therapies(271), Psoriasis: Treatment and Pathogenesis(227), Autoimmune and Inflammatory Disorders Research(103), Fibromyalgia and Chronic Fatigue Syndrome Research(43)

Publications458 total

Le bimekizumab a démontré une efficacité comparable à 1 an chez les hommes et femmes atteints de spondyloarthrite axiale : résultats de deux études de Phase III
Revue du Rhumatisme·2025
Real‐World Use of Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs in Patients With Axial Spondyloarthritis in the United States: Persistence, Variables Associated With Persistence, and Dosing Variations
Pharmacoepidemiology and Drug Safety·2025Open Access
A Real-World Comparison of Clinical Effectiveness of Upadacitinib, Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors in Patients with Axial Spondyloarthritis After Switching from an Initial Tumor Necrosis Factor Inhibitor Treatment
Rheumatology and Therapy·2025Open Access
Ixekizumab and Malignant Neoplasms
JAMA Dermatology·2025· 1 citedOpen Access
Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab
Therapeutic Advances in Musculoskeletal Disease·2025· 2 citedOpen Access
1081 A Retrospective Observational Study on the Relationship Between Cost-of-Living Crisis (CoLC) and Hot Water Bottle Related Burn (HWBB)
British journal of surgery·2025Open Access
P165 Bimekizumab impact on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) core domains for patients with psoriatic arthritis: results up to 2 years of treatment duration
Lara D. Veeken·2025Open Access
Divergent B-cell and cytotoxic TNK cell activation signatures in HLA-B27-associated ankylosing spondylitis and acute anterior uveitis
Frontiers in Immunology·2025· 6 citedOpen Access
Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study
Arthritis Research & Therapy·2025· 5 citedOpen Access
Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies
Lara D. Veeken·2025· 6 citedOpen Access
Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular Events
Dermatology and Therapy·2025· 4 citedOpen Access
Faible taux d’uvéites chez les patients atteints de spondyloarthrite axiale ou de rhumatisme psoriasique traités par bimekizumab : résultats à long terme des essais de phase IIb/III
Revue du Rhumatisme·2024
AB1443 CONSISTENT SAFETY PROFILE OF SECUKINUMAB IN PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS: UPDATE ON THE DATA FROM POOLED CLINICAL TRIALS
Annals of the Rheumatic Diseases·2024
POS0050 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 2-YEAR DATA FROM THE PHASE 3 SELECT-AXIS 2 STUDY
Annals of the Rheumatic Diseases·2024
P171 Bimekizumab impact on core group for research and assessment of psoriasis and psoriatic arthritis domains for patients with psoriatic arthritis: 52-week results from four phase 3 studies
Lara D. Veeken·2024· 1 cited
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2
RMD Open·2024· 2 citedOpen Access
E065 Disagreement between patient and physician global assessment over time in psoriatic arthritis: insight into treatment priorities
Lara D. Veeken·2024Open Access
Combination biologics or targeted synthetic disease-modifying anti-rheumatic drugs in the treatment of spondyloarthritis: a systematic literature review
Expert Review of Clinical Immunology·2024· 2 cited
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials
Dermatology and Therapy·2024· 10 citedOpen Access
Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials
Arthritis Research & Therapy·2024· 20 citedOpen Access
page 1 of 23Next →

Frequent Co-authors

Désirée van der Heijde(17), Jürgen Braun(13), Xenofon Baraliakos(13), Joachim Sieper(12), Philip J. Mease(12), Walter P. Maksymowych(10), Robert Landewé(9), Lianne S. Gensler(8), Filip Van den Bosch(8), Robert D. Inman(7), Alice B. Gottlieb(6), Martín Rudwaleit(6), Maxime Dougados(5), Brian Porter(5), Christopher T. Ritchlin(5), Bengt Hoepken(5), Maureen Dubreuil(4), David Tak Yan Yu(4), Nigil Haroon(4), Amit Shah(4)